SGLT2 inhibitors significantly decreased the rate of hospitalization for HF (RR 0.73, 95% CI: 0.61-0.88) with no significant change in mortality (RR 1.05, 95% CI: 0.78-1.40), all-cause hospitalization (RR 1.00, 95% CI: 0.84-1.17), and cardiovascular death (RR 1.03, 95% CI: 0.83-1.28). This evidence concerns the gene SLC5A2 and hydrops fetalis.